CHELSEA GREENWOOD: Open Payments
NPI 1740063890 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,796 in 88 payments from 21 companies in 2025. Trend: 2023 $33 · 2024 $1,677 · 2025 $1,796
Food & beverage: $1,796
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $325 |
| ABBVIE INC. | 16 | $258 |
| Novo Nordisk Inc | 10 | $162 |
| PFIZER INC. | 6 | $125 |
| Sumitomo Pharma America, Inc. | 5 | $124 |
| GlaxoSmithKline, LLC. | 6 | $116 |
| Amgen Inc. | 6 | $98 |
| Aimmune Therapeutics, Inc. | 4 | $95 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $67 |
| Corcept Therapeutics | 2 | $61 |
Products named: BREZTRI, GEMTESA, TRELEGY ELLIPTA, ELIQUIS, ZENPEP, VRAYLAR, AIRSUPRA, LINZESS.
Industry payments across AZ — which companies pay providers there.
